Voleon Capital Management LP Sells 8,304 Shares of UnitedHealth Group Incorporated $UNH

Voleon Capital Management LP cut its position in shares of UnitedHealth Group Incorporated (NYSE:UNH - Free Report) by 64.1% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,658 shares of the healthcare conglomerate's stock after selling 8,304 shares during the period. Voleon Capital Management LP's holdings in UnitedHealth Group were worth $2,440,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Citizens National Bank Trust Department lifted its stake in shares of UnitedHealth Group by 1.0% in the 1st quarter. Citizens National Bank Trust Department now owns 17,886 shares of the healthcare conglomerate's stock valued at $9,368,000 after purchasing an additional 170 shares during the last quarter. Fort Washington Investment Advisors Inc. OH lifted its stake in shares of UnitedHealth Group by 0.3% during the 1st quarter. Fort Washington Investment Advisors Inc. OH now owns 530,103 shares of the healthcare conglomerate's stock worth $277,641,000 after acquiring an additional 1,465 shares during the last quarter. Caitlin John LLC lifted its stake in shares of UnitedHealth Group by 14.8% during the 1st quarter. Caitlin John LLC now owns 862 shares of the healthcare conglomerate's stock worth $451,000 after acquiring an additional 111 shares during the last quarter. Sherbrooke Park Advisers LLC purchased a new position in UnitedHealth Group during the 4th quarter worth $515,000. Finally, Silvercrest Asset Management Group LLC increased its holdings in UnitedHealth Group by 47.8% during the 4th quarter. Silvercrest Asset Management Group LLC now owns 38,796 shares of the healthcare conglomerate's stock worth $19,625,000 after purchasing an additional 12,550 shares during the period. 87.86% of the stock is owned by institutional investors.

UnitedHealth Group Stock Performance

Shares of UNH stock opened at $320.46 on Tuesday. The stock has a market capitalization of $290.24 billion, a PE ratio of 13.88, a price-to-earnings-growth ratio of 2.04 and a beta of 0.45. The company has a quick ratio of 0.85, a current ratio of 0.85 and a debt-to-equity ratio of 0.73. The stock's 50-day moving average price is $288.96 and its 200 day moving average price is $371.54. UnitedHealth Group Incorporated has a 52-week low of $234.60 and a 52-week high of $630.73.

UnitedHealth Group (NYSE:UNH - Get Free Report) last released its earnings results on Tuesday, July 29th. The healthcare conglomerate reported $4.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.45 by ($0.37). The business had revenue of $111.62 billion for the quarter, compared to analyst estimates of $111.75 billion. UnitedHealth Group had a return on equity of 23.32% and a net margin of 5.04%.The business's revenue for the quarter was up 12.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $6.80 EPS. UnitedHealth Group has set its FY 2025 guidance at 16.000- EPS. As a group, equities research analysts forecast that UnitedHealth Group Incorporated will post 29.54 EPS for the current year.

UnitedHealth Group Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 23rd. Investors of record on Monday, September 15th will be issued a $2.21 dividend. The ex-dividend date is Monday, September 15th. This represents a $8.84 dividend on an annualized basis and a dividend yield of 2.8%. UnitedHealth Group's dividend payout ratio is currently 38.30%.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the company. Cantor Fitzgerald reiterated an "overweight" rating and issued a $440.00 price target on shares of UnitedHealth Group in a report on Tuesday, August 26th. Baird R W downgraded UnitedHealth Group from a "hold" rating to a "strong sell" rating in a research report on Thursday, July 31st. UBS Group reiterated a "buy" rating on shares of UnitedHealth Group in a research report on Thursday, July 17th. Deutsche Bank Aktiengesellschaft lowered their price target on UnitedHealth Group from $521.00 to $362.00 and set a "buy" rating on the stock in a research report on Wednesday, May 14th. Finally, TD Cowen cut UnitedHealth Group from a "buy" rating to a "hold" rating and set a $308.00 target price for the company. in a report on Monday, May 19th. Sixteen equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and three have issued a Sell rating to the company's stock. Based on data from MarketBeat.com, UnitedHealth Group currently has a consensus rating of "Moderate Buy" and a consensus price target of $354.86.

UnitedHealth Group Company Profile

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage.

Want to see what other hedge funds are holding UNH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for UnitedHealth Group Incorporated (NYSE:UNH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.